Systemic Immunotherapies

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

This study observed that inflammation in androgenetic alopecia samples was similar to alopecia areata controls, but infundibular and isthmic inflammation were significantly more common in androgenetic alopecia cases.

This review discusses platelet-rich plasma and cell-based therapies for hair loss, noting promising results but emphasizing the need for standardization and robust trials to confirm their efficacy.

This article reviews advancements in hair transplantation, highlighting robotic and follicular unit techniques, and discusses adjuvant modalities like platelet-rich plasma, lasers, and stem cells without reporting new clinical results.

This article reviews potential therapeutic targets and comorbidities associated with male androgenetic alopecia, but reports no new clinical results; further study is needed for comprehensive management.

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

This perspective highlights the role of inflammation in male and female pattern hair loss and its implications for developing future therapeutic options.

This study reported that weekly intramuscular dexpanthenol may improve quality of life and satisfaction with hair appearance in women with female pattern hair loss, with no side effects observed.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

In this study, nine male cases of androgenetic alopecia showed marked improvement after receiving systemic dexpanthenol treatment.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This review examines complementary and alternative medicine for alopecia and finds limited support from robust clinical trials, highlighting the need for standardized studies to evaluate efficacy and safety.

This review identifies FDA-cleared home-use photobiomodulation devices for androgenetic alopecia treatment and highlights their excellent safety profile but notes the lack of long-term comparative studies.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

This study reviewed treatment options for alopecia areata totalis and universalis, finding no completely effective therapy. Promising treatments with quality data include diphenylcyclopropenone, squaric acid dibutylester, and photodynamic therapy, but larger, high-quality trials are needed.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This study found that apoptosis was more prevalent in hair follicles of women with female pattern hair loss, particularly in miniaturized follicles, and was associated with follicular inflammation.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This study found that intravenous high-dose pulse corticosteroids resulted in a complete response in 38% of children with alopecia areata, but the majority of responders relapsed within a year.

This study reported that adalimumab was well tolerated in patients with severe alopecia areata but did not lead to significant hair regrowth.

PGD2 stops hair growth and is higher in bald men with AGA.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study found that anti-TNF therapy-induced alopecia exhibits distinct clinical and histopathological features and can mimic psoriatic alopecia and alopecia areata, with some patients improving with topical treatment.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

In this study, researchers observed that follicular microinflammation significantly contributes to the early stages of male androgenetic alopecia, potentially leading to perifollicular fibrosis and follicle destruction as the condition progresses.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

Oral cyclosporin doesn't stop hair loss.

Inflammation may be linked to hair loss, and targeting specific enzymes could help treat it.

This study found that systemic corticosteroids led to satisfactory hair regrowth in 38.9% of severe alopecia areata patients, but hair fall occurred upon therapy discontinuation or tapering.

This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.

The document describes how to tell different types of non-scarring hair loss apart by looking at hair and scalp tissue under a microscope.